Micro-cap biotech Aridis Pharmaceuticals $ARDS got hammered this morning as investigators revealed that one of its clinical-stage drugs failed a mid-stage study, triggering safety fears and forcing the company to dump the program.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,